Skip to main content

Biopharma

Connexius Bioprocessing South Korea 2028

Date
24–25 May 2028
Location
Seoul, South Korea

Knowledge Hub

Download content relating to this event and topic.

Want to Sponsor This Event?

Explore sponsorship opportunities and discover how your brand can connect with key decision-makers across the industry.

Speak with our Sponsorship Team

Roshinee Singh

Head of Business Development

roshinee.singh@connexiusgroup.com

Jack Baclaan

Business Development Manager

jack.baclaan@connexiusgroup.com

Jumarie Albit

Business Development Manager

jumarie.albit@connexiusgroup.com

INSIGHTS

  • BiopharmaMarket insight

    Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?

    Biologics manufacturing productivity depends on more than installed bioreactor volume. This article compares four 2,000 L single-use bioreactors with one 10,000 L stainless-steel reactor and examines how turnaround time, utilisation, titre, downstream capacity and manufacturing strategy can determine annual output.

    Read more: Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?
  • BiopharmaMarket insight

    Stainless Steel vs Single-Use: Why Biomanufacturing Still Needs Both

    Stainless steel and single-use systems serve different roles in modern biomanufacturing, with the right choice depending on production volume, product mix and demand certainty. This article examines how leading APAC facilities are combining scale, flexibility and resilience through steel, single-use and hybrid manufacturing strategies.

    Read more: Stainless Steel vs Single-Use: Why Biomanufacturing Still Needs Both
  • BiopharmaMarket insight

    Why Singapore Is Emerging as Biopharma’s China+1 Hub

    Singapore’s biopharmaceutical sector is navigating short-term production volatility while strengthening its long-term position as a trusted bridge between China and Western markets. This article examines how Singapore’s regulatory credibility, advanced manufacturing ecosystem and geopolitical neutrality support its emerging role as a China+1 hub for global biopharma.

    Read more: Why Singapore Is Emerging as Biopharma’s China+1 Hub